<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03067597</url>
  </required_header>
  <id_info>
    <org_study_id>000261</org_study_id>
    <nct_id>NCT03067597</nct_id>
  </id_info>
  <brief_title>An Open-label Trial Investigating the Efficacy and Safety of a Vaginal Insert in Pregnant Women at Term</brief_title>
  <official_title>A Multicentre, Open-label Phase III Trial Investigating the Efficacy and Safety of FE 999901 Vaginal Insert in Pregnant Women at Term (≥37 Weeks and &lt;41 Weeks of Gestation) Requiring Cervical Ripening</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate the efficacy of controlled-release dinoprostone vaginal insert (DVI) for
      cervical ripening success (either Bishop Score (BS) ≥7 or vaginal delivery) within 12 hours
      of vaginal insert administration.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 22, 2017</start_date>
  <completion_date type="Actual">February 24, 2018</completion_date>
  <primary_completion_date type="Actual">February 24, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of women with cervical ripening success</measure>
    <time_frame>Within 12 hours of vaginal insert administration</time_frame>
    <description>Defined as either Bishop Score (BS) ≥7 or a vaginal delivery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of nulliparous and multiparous subjects with cervical ripening success</measure>
    <time_frame>Within 12 hours of Investigational Medicinal Product (IMP) administration</time_frame>
    <description>Collected labour data and delivery data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects delivering vaginally</measure>
    <time_frame>Within 12 hours of IMP administration</time_frame>
    <description>Collected labour data and delivery data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects delivering vaginally</measure>
    <time_frame>Within the first admission to hospital</time_frame>
    <description>Collected labour data and delivery data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with a BS increase ≥3 points from baseline</measure>
    <time_frame>Within 12 hours of IMP administration</time_frame>
    <description>Measured by BS assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who have a caesarean delivery within the first admission to hospital</measure>
    <time_frame>At time of delivery</time_frame>
    <description>Data collected during the first admission to hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who receive pre-delivery oxytocic drugs and dose of pre-delivery oxytocic drugs</measure>
    <time_frame>From the IMP removal to delivery</time_frame>
    <description>Collected pre-delivery data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who undergo mechanical cervical ripening</measure>
    <time_frame>At least 60 minutes after the removal of the IMP</time_frame>
    <description>Collected labour data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical cervical ripening for subjects who undergo mechanical cervical ripening</measure>
    <time_frame>Time from at least 60 minutes after the removal of the IMP until end of any mechanical ripening</time_frame>
    <description>Measured as start date and time of first mechanical ripening and the end date and time of last mechanical ripening</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with BS ≥7</measure>
    <time_frame>At onset of labour</time_frame>
    <description>Among those having onset of labour while IMP is in-situ</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from IMP administration to onset of active labour</measure>
    <time_frame>Interval from IMP administration to onset of active labour</time_frame>
    <description>Within the first admission to hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from IMP administration to vaginal delivery, caesarean delivery and any delivery</measure>
    <time_frame>Interval from IMP administration to delivery</time_frame>
    <description>Within the first admission to hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type, frequency and intensity of intrapartum adverse events (AEs), postpartum AEs and neonatal AEs</measure>
    <time_frame>From obtaining the informed consent through end of trial (expected average of up to 1 week)</time_frame>
    <description>Assessed up to time when the subjects are discharged from the hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Type, frequency and intensity of intrapartum AEs</measure>
    <time_frame>From obtaining the informed consent to the removal of the IMP</time_frame>
    <description>Assessed up to time when the deliveries occur</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in maternal parameters of vital signs (blood pressure, heart rate and body temperature)</measure>
    <time_frame>From baseline through end of trial (expected average of up to 1 week)</time_frame>
    <description>Assessed up to time when the subjects are discharged from the hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in maternal parameters of haematology, clinical chemistry and urinalysis</measure>
    <time_frame>From baseline to end of trial (expected average of up to 1 week)</time_frame>
    <description>Assessed up to time when the subjects are discharged from the hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of neonates with Apgar Score &lt;7</measure>
    <time_frame>5 minutes post-birth</time_frame>
    <description>Measured as Apgar Score assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pH in umbilical artery blood samples</measure>
    <time_frame>At birth</time_frame>
    <description>pH evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of admission to neonatal intensive care unit (NICU) for at least 24 hours</measure>
    <time_frame>After delivery</time_frame>
    <description>Admission/discharge data from NICU</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Cervical Ripening</condition>
  <arm_group>
    <arm_group_label>Dinoprostone vaginal insert (DVI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dinoprostone</intervention_name>
    <description>The DVI contains 10 mg dinoprostone</description>
    <arm_group_label>Dinoprostone vaginal insert (DVI)</arm_group_label>
    <other_name>CERVIDIL®</other_name>
    <other_name>PROPESS®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant women at term (≥37 weeks 0 day and &lt; 41 weeks 0 day of gestation) at the
             Baseline visit

          -  Candidate for pharmacologic induction of labour

          -  Singleton pregnancy with live infant in vertex presentation

          -  Baseline BS ≤ 4 at the Baseline visit

          -  Parity ≤ 3 (parity is defined as one or more births live or stillbirths after 22 weeks
             0 day gestation)

          -  Written informed consent

        Exclusion Criteria:

          -  Women in active labour

          -  Presence of uterine or cervical scar including scar from previous caesarean section,
             and previous cone biopsy of the cervix and loop electrosurgical excision procedure
             (LEEP)

          -  Uterine abnormality e.g. bicornuate uterus

          -  Administration of oxytocin, any cervical ripening or labour inducing agents (including
             mechanical methods) or a tocolytic drug within 7 days prior to IMP administration.
             Magnesium sulfate is permitted if prescribed as treatment for preeclampsia or
             pregnancy induced hypertension

          -  Presence of the following conditions/symptoms:

        Systolic blood pressure &gt; 160 mmHg or diastolic blood pressure &gt; 110 mmHg. Platelets &lt;
        100,000/µL. Increased liver function tests (2x upper limits of normal range). Severe,
        persistent right upper quadrant/epigastric pain. Progressive renal insufficiency:
        Creatinine &gt; 1.1 mg/dL, Doubling of creatinine in the absence of other renal disease.
        Pulmonary edema. New onset cerebral or visual disturbances.

          -  Suspected or confirmed cephalopelvic disproportion and/or fetal malpresentation

          -  Diagnosed congenital abnormalities, not including polydactyly

          -  Suspected or confirmed intrauterine growth retardation (≤ mean 1.5 SD of normal
             estimated fetal weight for dates)

          -  Any evidence of fetal compromise at Baseline visit (e.g., non-reassuring fetal heart
             rate pattern, meconium staining, history of non-reassuring fetal status or abnormal
             umbilical artery Doppler wave form)

          -  Intake of medication with aspirin or non-steroidal anti-inflammatory drugs (NSAIDs) at
             V2

          -  Ruptured membranes ≥ 48 hours prior to IMP administration

          -  Suspected clinical chorioamnionitis

          -  Current pelvic inflammatory disease, unless adequate prior treatment has been
             instituted

          -  Fever (axillary temperature ≥ 38.0°C) at the Baseline visit

          -  Any condition in which vaginal delivery is contraindicated (e.g., placenta previa or
             any unexplained vaginal bleeding at any time after 24 weeks 0 day during this
             pregnancy)

          -  Known or suspected allergy to, dinoprostone, other prostaglandins or any constituent
             of IMP

          -  Any condition urgently requiring delivery

          -  History of asthma or glaucoma

          -  Unable to comply with the protocol

          -  Any other medical condition which in the judgement of the investigators would impair
             participation in the trial
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Development Support</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yokota Maternity Hospital</name>
      <address>
        <city>Maebashi</city>
        <state>Gunma</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kitasato University Hospital</name>
      <address>
        <city>Sagamihara</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Medical Center and Research Institute for Maternal and Child Health</name>
      <address>
        <city>Izumi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamamatsu University Hospital</name>
      <address>
        <city>Hamamatsu</city>
        <state>Shizuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seirei Hamamatsu General Hospital</name>
      <address>
        <city>Hamamatsu</city>
        <state>Shizuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jichi Medical University Hospital</name>
      <address>
        <city>Shimotsuke</city>
        <state>Tochigi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Itabashi Chuo Medical Center</name>
      <address>
        <city>Itabashi</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tsukuba Hospital</name>
      <address>
        <city>Ibaraki</city>
        <state>Tsukuba</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hori Hospital</name>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rinku General Medical Center</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juntendo University Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keio University Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Tokyo Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tokyo Metropolitan Bokutoh Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2017</study_first_submitted>
  <study_first_submitted_qc>February 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2017</study_first_posted>
  <last_update_submitted>March 7, 2018</last_update_submitted>
  <last_update_submitted_qc>March 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dinoprostone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

